DENALI THERAPEUTICS INC (DNLI)
Health Care · biotechnology · NASDAQ
Denali Therapeutics is a clinical-stage biotechnology company developing blood-brain barrier-penetrating therapeutics to treat neurodegenerative and lysosomal storage diseases.
What DENALI THERAPEUTICS INC does
Denali Therapeutics is a biopharmaceutical company focused on developing therapies for neurodegenerative and lysosomal storage diseases. The company utilizes a proprietary blood-brain barrier (BBB) platform, specifically its Transport Vehicle (TV) technology, to enhance the delivery of therapeutic molecules into the brain. Its clinical and research pipeline targets conditions such as Hunter syndrome and other neurodegenerative disorders.
Themes: neuroscience / neurodegeneration, blood-brain barrier drug delivery, lysosomal storage diseases, drug development platform
Fundamentals
- Price$24.92 as of 2026-08-21 close
- Market cap$4.0B as of 2026-08-21
- 1-year return+63.6% 2025-08-21 close $15.23 → 2026-08-21 close $24.92
- P/En/a negative earnings
- Net margin-3539.2% as of 2026-08-24
- ROE-55.3% as of 2026-08-24
- Debt / equity0.01 as of 2026-08-24
- Beta1.01 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How DNLI compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
DNLI is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
56.9 #371 of 1,704 scored · #69 of 240 in Health Care
Catalysts 74th: analysts have raised their average price target by 2.7% since the prior reading; momentum 65th: over the past 3 months this stock beat the market by 26.0 percentage points; weakest is volume and participation 19th: trading volume is unusually light — only about 43% of its 30-day average.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How DENALI THERAPEUTICS INC looks technically
DENALI THERAPEUTICS INC (DNLI) is trading 22.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 186 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 43% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 22.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +22.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $24.32 | $24.32 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $20.37 | $20.37 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 25.74. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 186 trading days ago — a "golden cross", a bullish long-term signal | 186 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 16, below the 25 that marks a real trend) | 15.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 54.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($23.23 to $25.74) — its "stochastic" reading is 67 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 67.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $27.30 | $27.30 |
|---|---|---|
| From the 52-week high | it is 8.7% below its 52-week high (its highest price of the past year) | -8.7% |
| Above the 52-week low | it is 98.1% above its 52-week low (its lowest price of the past year) | +98.1% |
| Below the 52-week high | it is 8.7% below its highest point of the past year | 8.7% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 32 trading days ago | 32 sessions |
| All-time high | its highest closing price on record is $93.94 (set on 2020-12-22) | $93.94 |
| Given back of the 52-week move | over the past year its closes ranged ($12.75 to $27.21), and it has given back roughly a quarter of its rise from last year’s low — 16% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $17.81 to $18.27. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 15.8% |
| From the all-time high | it is 73.5% below its all-time high | -73.5% |
| Nearest price level | it is trading 2.8% below a resistance level at $25.61 — a price it turned at four times since 2024-10-10, most recently on 2026-08-07. Since 2024-08-21 it has 13 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.8% |
| All-time low | its lowest closing price on record is $10.57 (set on 2025-04-07) | $10.57 |
| Above the all-time low | it is 135.8% above its all-time low | +135.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 1st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.9725 between its high and its low — about 3.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.9725 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $23.12 and $25.73 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $23.12 – $24.43 – $25.73 |
| Typical daily range (% of price) | its price moves about 3.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.9% |
| Stretch from the 200-day average | it is trading 4.7 daily ranges above its 200-day average price (22.4% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 43% of its 30-day average | 0.43× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 2.7% since the prior reading | +2.7% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
|---|---|---|
| Since a bearish engulfing | 8 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 8 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.2% |
|---|---|---|
| Open gap | it gapped 2.1% below the previous close 1 session ago and has not traded back through the level it left behind at 25.69 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.1% |
| Gap filled | a 2.8% gap up opened on 2026-08-07 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 10 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -3% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 2.2 percentage points (the stock gained 4.6% while the market gained 2.3%) | +2.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 26.0 percentage points (the stock gained 29.1% while the market gained 3.1%) | +26.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 12.4 percentage points (the stock gained 23.4% while the market gained 11.1%) | +12.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 43.1 percentage points (the stock gained 63.6% while the market gained 20.5%) | +43.1% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 4.0% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.8% of the share price. | +4.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 17% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $21.22 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +17.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $24.84 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +0.3% |
Price levels it has turned at before
DNLI last closed at $24.92 on 2026-08-21. Since 2024-08-21 it has turned at 13 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $25.61 | Resistance | 2.8% above the last close | turned there four times · 2024-10-10 to 2026-08-07 |
| $23.59 | Support | 5.3% below the last close | turned there three times · 2024-11-19 to 2026-03-25 |
| $22.68 | Support | 9.0% below the last close | turned there three times · 2025-02-20 to 2026-08-03 |
| $21.88 | Support | 12.2% below the last close | turned there three times · 2026-03-10 to 2026-07-15 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $25.74.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 6 trading days, since 2026-08-14.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · macd · breakout · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.20 mean, 1=Strong Buy…5=Strong Sell) — 16 analysts
- Mean price target$35.44 range $27.00 – $42.00; median $35.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DNLI
- Consensus EPS estimate-$0.4058 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High dependency on the successful development of the blood-brain barrier platform and clinical trial outcomes.","Significant history of net losses and potential future requirement for additional financing to fund operations.","Risks associated with regulatory approval, commercialization, and market acceptance of products like AVLAYAH."]
What changed in the latest 10-Q
AI-assisted comparison of DNLI's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-07) adds: 'BBB platform technology, programs, and biomarkers' (instead of 'BBB platform, programs, and biomarkers')
- Newer filing (2026-05-07) adds statement: 'We currently have one approved product. Our commercial product, AVLAYAH TM (tividenofusp alfa-eknm) received U.S. Food and Drug Administration ("FDA") approval on March 24, 2026 and is approved for the treatment of neurologic manifestations in patients with Hunter syndrome or mucopolysaccharidoses II (MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial. We began commercial distribution of AVLAYAH in April 2026.'
- Newer filing (2026-05-07) adds: 'the approval of AVLAYAH is based on the reduction of a key disease biomarker, cerebrospinal fluid heparan sulf'
- Removed:
- Older filing (2025-11-06) removed: 'preclinical studies,' (replaced with 'preclinical studies and')
- Older filing (2025-11-06) removed: 'our plans and ability to establish sales, marketing, manufacturing, and distribution infrastructure to commercialize any product candidates for which we obtain approval'
- Older filing (2025-11-06) removed: 'our plans and ability to develop our own manufacturing facilities'
- Older filing (2025-11-06) removed: 'the pricing and reimbursement of our product candidates, if approved and commercialized'
- Older filing (2025-11-06) removed: 'changes in currency exchange rates and currency controls'
- Older filing (2025-11-06) removed: 'the global pandemic, tariffs and trade barriers'
- Older filing (2025-11-06) removed strategy section containing clinical program details about Tividenofusp alfa and DNL126
- Reworded:
- Newer filing (2026-05-07) changed: 'Transport Vehicle TM ("TV")' to 'Transport Vehicle TM ("TV")' - shift from 'TransportVehicle TM ("TV")' in older filing
- Newer filing (2026-05-07) changed strategy point 1 from 'Discover and develop a new class' to 'Discover: Invent a new class' with restructured format
- Newer filing (2026-05-07) changed strategy point 2 from standalone to 'Develop: Accelerate and expand' format
- Newer filing (2026-05-07) changed strategy point 3 from 'Launch' to 'Deliver: Launch' format
- Newer filing (2026-05-07) changed: 'our ability to successfully market, manufacture, and commercialize AVLAYAH and any other products' (product-specific language) replacing older general language
- Newer filing (2026-05-07) changed: 'our ability to successfully conduct in-house manufacturing' replacing 'our plans and ability to develop our own manufacturing facilities'
- Newer filing (2026-05-07) changed: 'the pricing and reimbursement of AVLAYAH and any other product candidates that receive approval' (specific product reference) replacing conditional 'if approved and commercialized'
- Notes:
- Older filing text appears truncated at end ('with the goal o'), limiting full comparison of clinical program sections
- Newer filing text also appears truncated at end ('cerebrospinal fluid heparan sulf'), limiting full assessment of biomarker discussion
- Comparison limited by truncation but core additions, removals, and wording changes are identifiable in non-truncated portions
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
Most recent open-market transaction: 2026-01-06. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DNLI's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding DNLI as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 24,232,826
- Reported value $465,270,264
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
DNLI had 17,434,654 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
DNLI had 10.9% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.12 days to cover at the same settlement.
- Reported short interest (shares) 17,434,654
- Short interest (% of shares outstanding) 10.9%
- Prior settlement (shares) 16,035,916
- Reported change 8.72%
- Days to cover (reported) 12.12
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Biogen (BIIB)
- Roche (RHHBY)
- Sanofi (SNY)
- Takeda Pharmaceutical (TAK)
- AbbVie (ABBV)
- Ionis Pharmaceuticals (IONS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare DNLI vs…
Frequently asked questions
What does DENALI THERAPEUTICS INC (DNLI) do?
Denali Therapeutics is a biopharmaceutical company focused on developing therapies for neurodegenerative and lysosomal storage diseases. The company utilizes a proprietary blood-brain barrier (BBB) platform, specifically its Transport Vehicle (TV) technology, to enhance the delivery of therapeutic molecules into the brain. Its clinical and research pipeline targets conditions such as Hunter syndrome and other neurodegenerative disorders.
What sector is DENALI THERAPEUTICS INC (DNLI) in?
DENALI THERAPEUTICS INC (DNLI) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are DENALI THERAPEUTICS INC's (DNLI) competitors?
Notable peers of DENALI THERAPEUTICS INC (DNLI) include Biogen, Roche, Sanofi, Takeda Pharmaceutical and AbbVie. This peer set is informational only — not financial advice.
Is DENALI THERAPEUTICS INC (DNLI) overbought or oversold right now?
DENALI THERAPEUTICS INC (DNLI) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DNLI come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.